Peter Bradding
YOU?
Author Swipe
View article: Assessment of an Oral Corticosteroid Withdrawal Pathway for Severe Asthma Patients Receiving Biologic Therapies
Assessment of an Oral Corticosteroid Withdrawal Pathway for Severe Asthma Patients Receiving Biologic Therapies Open
Most clinically stable patients with asthma receiving biologics successfully withdrew mOCS without requiring dynamic adrenal function testing.
View article: TGFβ1 generates a pro-fibrotic proteome in human lung parenchyma that is sensitive to pharmacological intervention
TGFβ1 generates a pro-fibrotic proteome in human lung parenchyma that is sensitive to pharmacological intervention Open
A pro-fibrotic proteome is induced in human lung parenchyma exposed to TGFβ1, sensitive to pharmacological intervention. This approach has the potential to enhance therapeutic drug screening for IPF treatment.
View article: Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma
Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma Open
Background ∼5–10% of patients with asthma have severe disease. A proportion remain symptomatic despite suppression of T2-related inflammation but what drives persistent symptoms remains unclear. Eicosanoids exert a functional role in pulmo…
View article: The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential
The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential Open
Idiopathic pulmonary fibrosis (IPF) is a severe lung disease affecting around 5 million people globally, with a median survival of 3-4 years. Characterized by excessive scarring of lung tissue, IPF results from the accumulation of myofibro…
View article: Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor <scp>MTPS9579A</scp> in asthma
Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor <span>MTPS9579A</span> in asthma Open
Background Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti‐tr…
View article: BS59 The k+ channel KCa3.1 as a novel target for aortic stenosis
BS59 The k+ channel KCa3.1 as a novel target for aortic stenosis Open
Introduction & Aim Aortic stenosis (AS) is characterised by the progressive accumulation of fibrotic extracellular matrix and calcific mineral within the aortic valve (AV). These structural changes result in reduced leaflet mobility and le…
View article: The effects of inhaled corticosteroids on healthy airways
The effects of inhaled corticosteroids on healthy airways Open
Background The effects of inhaled corticosteroids (ICS) on healthy airways are poorly defined. Objectives To delineate the effects of ICS on gene expression in healthy airways, without confounding caused by changes in disease‐related genes…
View article: Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study Open
Background: The anti-IgE monoclonal antibody omalizumab is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during 1 year of omalizumab treatment. Methods: One-year open-label Study o…
View article: Airway hyperresponsiveness in asthma: The role of the epithelium
Airway hyperresponsiveness in asthma: The role of the epithelium Open
Airway hyperresponsiveness (AHR) is a key clinical feature of asthma. The presence of AHR in people with asthma provides the substrate for bronchoconstriction in response to numerous diverse stimuli, contributing to airflow limitation and …
View article: The effects of inhaled corticosteroids on healthy airways
The effects of inhaled corticosteroids on healthy airways Open
Rationale The effects of inhaled corticosteroids (ICS) on healthy airways are poorly defined. Objectives To delineate the effects of ICS on gene expression in healthy airways, without confounding caused by changes in disease-related genes …
View article: S91 The effects of inhaled corticosteroids on healthy airways
S91 The effects of inhaled corticosteroids on healthy airways Open
Background The effects of inhaled corticosteroids (ICS) on healthy airways are poorly described. Delineating their effects on gene expression in health, without the confounding changes generated by changes in disease-related genes, will en…
View article: M18 Assessing ICS responsiveness in severe asthma using BDP/formoterol NEXThaler™ dose-counting
M18 Assessing ICS responsiveness in severe asthma using BDP/formoterol NEXThaler™ dose-counting Open
Background 65% of people with severe asthma and FeNO ≥45 ppb are non-adherent to inhaled corticosteroids (ICS). Digital monitoring that records both time-of-use and inhaler technique can identify non-adherence and ICS responsiveness, but t…
View article: Enabling Adults With Severe Asthma to Exercise: A Qualitative Examination of the Challenges for Patients and Health Care Professionals
Enabling Adults With Severe Asthma to Exercise: A Qualitative Examination of the Challenges for Patients and Health Care Professionals Open
Patients identified the important role of HCPs in supporting and advising on lifestyle change. Despite a preference for supervised exercise programs, both patient and HCP barriers existed. To meet patients' varied support needs, improved i…
View article: Identification of redundancy between human <scp>FcεRIβ</scp> and <scp>MS4A6A</scp> proteins points toward additional complex mechanisms for <scp>FcεRI</scp> trafficking and signaling
Identification of redundancy between human <span>FcεRIβ</span> and <span>MS4A6A</span> proteins points toward additional complex mechanisms for <span>FcεRI</span> trafficking and signaling Open
Background Allergic diseases are triggered by signaling through the high‐affinity IgE receptor, FcεRI. In both mast cells (MCs) and basophils, FcεRI is a tetrameric receptor complex comprising a ligand‐binding α subunit (FcεRIα), a tetrasp…
View article: CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis
CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis Open
Progressive fibrosing interstitial lung diseases (PFILDs) cause substantial morbidity and mortality. Antifibrotic agents slow progression, but most of the clinical need remains unmet. The archetypal PFILD is idiopathic pulmonary fibrosis (…
View article: Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation Open
Background In T2‐mediated severe asthma, biologic therapies, such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether they provide inf…
View article: Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma
Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma Open
Background The most recognizable phenotype of severe asthma comprises people who are blood eosinophil and FeNO‐high, driven by type 2 (T2) cytokine biology, which responds to targeted biological therapies. However, in many people with seve…
View article: Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes
Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes Open
Rationale: The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although present in a mino…
View article: Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells
Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells Open
The mechanisms underlying corticosteroid insensitivity in severe asthma have not been elucidated although some indirect clinical evidence points toward a role of mast cells. Here, we tested the hypothesis that mast cells can drive corticos…
View article: S92 FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
S92 FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma Open
Rationale Patients with severe asthma, raised fractional exhaled nitric oxide (FeNO) and high blood eosinophil (Eos) counts are at increased risk of asthma attacks. Objective To investigate this relationship by correlating FeNO and blood E…
View article: Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis Open
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved treatments for IPF but have limited efficacy and their …
View article: Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma Open
Background Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. Methods We reviewed patient choice to follow HCP advice t…
View article: Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors Open
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpres…
View article: Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Open
Inhaled corticosteroids (ICS) are the core component of asthma treatment and the only maintenance therapy known to prevent asthma death. There is currently no evidence that biologics prevent asthma death in people with asthma, and as such,…